Citations as recorded by:

1. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy

Oncotarget, 2017, 8 p. 55715

DOI: 10.18632/oncotarget.18382

Citations as recorded by: Cross Ref PMC Google

2. Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo

Metabolites, 2017, 7(3) p. 31

DOI: 10.3390/metabo7030031

Citations as recorded by: Cross Ref PMC Google

3. Metabolomic Profiling of the Synergistic Effects of Melittin in Combination with Cisplatin on Ovarian Cancer Cells

Metabolites, 2017, 7(2) p. 14

DOI: 10.3390/metabo7020014

Citations as recorded by: Cross Ref PMC Google

4. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased Pyruvate Kinase M2 (PKM2) Expression in Cervical Cancer Cells

Med Sci Monit, 2017, 23 p. 2017

DOI: 10.12659/MSM.901542

Citations as recorded by: Cross Ref PMC

5. Impact of the Pd2Spermine Chelate on Osteosarcoma Metabolism: An NMR Metabolomics Study

J. Proteome Res., 2017, 16(4) p. 1773

DOI: 10.1021/acs.jproteome.7b00035

Citations as recorded by: Cross Ref Google

6. A comprehensive insight into the clinicopathologic significance of miR-144-3p in hepatocellular carcinoma

Onco Targets Ther, 2017, 10 p. 3405

DOI: 10.2147/OTT.S138143

Citations as recorded by: Cross Ref PMC Google

7. Mammalian Target of Rapamycin (mTOR) Regulates Transforming Growth Factor-β1 (TGF-β1)-Induced Epithelial-Mesenchymal Transition via Decreased …

Year: 2017

Citations as recorded by: Google

8. Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature

Front. Pharmacol., 2016, 7

DOI: 10.3389/fphar.2016.00387

Citations as recorded by: Cross Ref PMC Google